RPTX - Repare Therapeutics

-

$undefined

N/A

(N/A)

Repare Therapeutics NASDAQ:RPTX Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor, and a Polθ inhibitor program.

Location: | Website: reparerx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-99.85M

Cash

152.8M

Avg Qtr Burn

-19.11M

Short % of Float

3.54%

Insider Ownership

1.01%

Institutional Own.

79.99%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Lunresertib (RP-6306) +/- Camonsertib (RP-3500) or Debio 0123 Details
Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer

Phase 3

Initiation

Phase 2

Data readout

Phase 1/2

Update

RP-1664 Details
Cancer, Neuroblastoma

Phase 1/2

Initiation

Phase 1

Data readout

RP-1664 Details
Cancer, Solid tumor/s

Phase 1

Data readout

RP-3467 +/- olaparib Details
Solid tumor/s, Cancer

Phase 1

Data readout

Phase 1

Update